The study could pave the way for the Trump administration to restrict how mifepristone is distributed and used, the Wall Street Journal has reported.

The reported study could allow the Trump administration to limit the distribution of the abortion pill by mail or telehealth services.

The full results are unlikely to be completed before November's midterm elections, the report said.

The Food and Drug Administration has launched a safety study of the abortion pill mifepristone, a senior FDA official confirmed to CBS News, a step that could pave the way for the…

Regulators maintain that the medication remains safe when used as directed

In May, the US Supreme Court ensured the abortion pill could continue to be prescribed through telemedicine and dispensed by mail when it restored a 2023 federal rule.

The effort is expected to take about six months, meaning its results would come after the midterm elections. | Health

The FDA's ongoing review of mifepristone could skip over established science, health experts warn

The FDA is going forward with an investigation into the safet | The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative…

Administration officials said the study is expected to take roughly six months, making it unlikely to be completed before voters head to the polls in November.

Roughly 7.5 million women have taken the pill over the past 25 years

The study could pave the way for the Trump administration to restrict how mifepristone is distributed and used, the Wall Street Journal has reported.